AIDS Therapies

Efavirenz Gets Class-A Status In New HHS Treatment Guide

Published in AIDS Weekly, December 21st, 1998

New HIV treatment guidelines for the first time list a drug other than a protease inhibitor as a linchpin of combination therapy.

Recommended highly active antiretroviral therapy (HAART) regimens have always been based on the use of at least one protease inhibitor. But a head-to-head clinical trial showed that one member of a different class of anti-HIV drugs can be as potent - for 36 weeks at least.

The new drug, the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz, attracted intense interest when these results were announced at the 1998 World AIDS Conference. The findings paved the way for so-called "protease-sparing" HAART...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-12-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry